Načítá se...
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists
Estrogen antagonists are universally employed in the breast cancer therapy, although antagonist therapy is limited by the inevitable development of cellular resistance. The molecular mechanisms by which these agents inhibit cellular proliferation in breast cancer cells are not fully defined. Recent...
Uloženo v:
| Vydáno v: | EMBO J |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC419909/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15141164/ https://ncbi.nlm.nih.govhttps://doi.org/10.1038/sj.emboj.7600231 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|